drugset / Trial / NCT00004268
Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension
Phase 2
Completed
300 enrolled
National Center for Research Resources (NCRR)
Roberts Pharmaceutical · collab
Treatment
Summary
OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.
Timeline
- Start
- 2001-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midodrine | Small molecule | — | Oral |